revealed that B7-H3 was overexpressed in breast cancer, and that upregulation of B7-H3 was correlated with poor prognosis and clinical outcomes in breast cancer, implying that B7-H3 could be a prospective target for CAR-T therapy (92). This evidence concerns the gene CD276 and breast carcinoma.